- Halozyme Therapeutics reported strong second quarter 2026 financial results with earnings per share of $2.28 and revenue reaching $481.00 million, surpassing analyst expectations.
- The biopharmaceutical company raised its full year 2026 guidance, projecting non GAAP EPS of $8.65 to $9.00 alongside increased commercial momentum from multiple collaboration agreements.
- Several financial institutions updated their ratings and target prices, reflecting overall positive market sentiment toward the company's growth platform.
